Ledger.Open graph →
SEC Form D · Amendment · filed June 16, 2022

Abata Therapeutics, Inc

Offering
$95.0M
Sold
$45.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (26)

Shelley Chu · CAMBRIDGE, MADirectorLorence Kim · CAMBRIDGE, MADirectorJohn Trzupek · CAMBRIDGE, MAExecAbbie Celniker · CAMBRIDGE, MADirectorSamantha Singer · CAMBRIDGE, MAExec · DirectorMitch Finer · CAMBRIDGE, MADirectorRichard Ronald · San Francisco, CADirectorD. S. Ruegg · San Francisco, CADirectorChristian Villela Klotz · Miami, FLExecJoshua Clemente · New York, NYDirectorRobert F. Garland · GREENWOOD VILLAGE, COExec · DirectorExpedition Fund III GP LP · Dallas, TXDirectorNagesh Mahanthappa · Cambridge, MADirectorSandy Lazzari · CAMBRIDGE, MAExecStephen Sofen · CAMBRIDGE, MAExecValerie Odegard · CAMBRIDGE, MADirectorBrian Hirsch · Cardiff-by-the-Sea, CADirectorRick Smith · Cardiff-by-the-Sea, CADirectorAllen Wolff · Cardiff-by-the-Sea, CADirectorBruce R. Winson · Dallas, TXDirectorC & C Development Co., LLC · Tustin, CAExecLadell Robbins · New York, NYExec · DirectorNagesh Mahanthappa · Cambridge, MADirectorSandy Lazzari · CAMBRIDGE, MAExecStephen Sofen · CAMBRIDGE, MAExecValerie Odegard · CAMBRIDGE, MADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗